Puntos clave
- 1There is no single cheapest source for every medicine — the best route depends on patent status, your coverage and the product.
- 2India appears in nearly every comparison because of manufacturing scale, statutory price ceilings, and originator voluntary licences.
- 3Run the six-question safety test on any seller: it requires a prescription for Rx-only, it names the manufacturer, it shows batch and expiry.
- 4Legality and safety are separate questions — a genuine product can still be illegal for you to import.
En esta página
1The five legitimate routes, compared
There is no single cheapest source for every medicine. The right route depends on whether the molecule is on-patent, whether you have insurance, and whether the product is temperature-sensitive.
| Route | Best for | Typical saving | Main caution |
|---|---|---|---|
| Domestic generic substitution | Off-patent everyday medicines | 60–90% | Brand-only prescriptions block it |
| Indian generic market | Off-patent and licensed molecules | 85–99% | Import rules and prescription validity |
| Government generic outlets | Essential medicines list items | 50–80% | Limited catalogue |
| Patient assistance programmes | On-patent branded therapy | Up to 100% | Income tested, paperwork heavy |
| Hospital and tender pricing | Injectables and infusions | 40–90% | Usually not available retail |
2Why India appears in almost every comparison
India manufactures a very large share of the world's generic medicine volume and produces many active pharmaceutical ingredients domestically. Several Indian facilities are inspected by the FDA, EMA and WHO because they export into those regulated markets.
Two further factors matter. First, India's pricing regulator caps the price of scheduled essential medicines, which anchors the whole market lower. Second, for several hepatitis C, HIV and cancer therapies, originator companies granted voluntary licences allowing Indian manufacturers to produce and supply lower-income markets legally.
That combination — scale, price ceilings and licensing — is why the gap is often 10× to 100× rather than the 2× to 3× you see between two Western countries.
3The six-question safety test for any source
Apply this to a local chain pharmacy, an online seller or an international supplier. A trustworthy source passes all six without hesitation.
- 1Does it require a valid prescription for prescription-only medicine? A source that does not is not a pharmacy.
- 2Is the manufacturer named on the listing, not just the salt?
- 3Can you see batch number, manufacturing date and expiry before purchase?
- 4Is there a named pharmacist or clinical contact you can question?
- 5Is there a verifiable physical address and a registration or licence number?
- 6Is the price merely low, or impossibly low relative to every other source for the same pack?
4Legality is separate from safety
A product can be perfectly genuine and still be illegal for you to import. Personal importation rules differ sharply between the United States, individual EU member states and the UK, and they change.
In broad terms, most jurisdictions treat small quantities for personal use, with a valid prescription and no commercial intent, differently from bulk import. But 'generally tolerated' is not the same as 'permitted', and customs officers apply the written rule.
Check your own national rule before ordering anything across a border, and never assume that what is legal for a neighbour applies to you.
Lo que muestra el dataset de Jivan
- 59×
- brecha de precios media
- 84%
- de los anclas supera 10×
- 344×
- mayor brecha documentada
Across our full referenced dataset, 476 referenced molecules average a 59× price gap, 84% of them are at least 10× cheaper in India, and the widest documented comparison is Colchicine at 344×. Across the full referenced dataset the gap is systematic rather than anecdotal: 84% of anchored molecules are at least 10× cheaper, with a 59× average ratio — a market-structure effect repeated across all 26 therapy areas.
Calculado en vivo desde 476 anchors
Preguntas frecuentes
For off-patent generics, India is consistently among the lowest-priced regulated markets, largely due to manufacturing scale and statutory price ceilings on essential medicines. For on-patent branded therapy, the cheapest route in most Western countries is usually a manufacturer patient assistance programme rather than any foreign purchase.
Price and quality are separate variables. Quality depends on the manufacturer's compliance with good manufacturing practice, which is why you should always identify the manufacturer rather than judging by price alone.
It depends entirely on your country and the specific medicine. Some jurisdictions allow limited personal-use quantities with a prescription; others prohibit import of prescription medicines outright. Check your national regulator before ordering.
Fuentes y lectura adicional
Cada afirmación anterior es rastreable hasta una fuente primaria pública. Citamos reguladores y organismos de salud pública, no vendedores comerciales.
- 1WHO Prequalification of Medical ProductsWorld Health Organization
- 2Central Drugs Standard Control OrganisationGovernment of India, CDSCO
- 3National Pharmaceutical Pricing Authority — Price CeilingsGovernment of India, NPPA
- 4Personal Importation of MedicinesU.S. Food & Drug Administration
- 5Find a Safe Online PharmacyNational Association of Boards of Pharmacy
- 6Pradhan Mantri Bhartiya Janaushadhi PariyojanaGovernment of India
Cómo se creó este artículo
Escrito e investigado
Health Affordability Editor, Jivan Editorial TeamRevisado editorialmente
Editorial Review Board — Jivan
Sources checked against Tier-1/Tier-2 references.
Aviso médico importante
Consulta siempre a un médico antes de cambiar de medicamento, dosis o marca. Jivan ofrece información educativa y de precios y no sustituye el diagnóstico ni la atención de urgencia.